Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Before acquisition by Celgene, Acetylon spins out some HDAC inhibitor assets into Regenacy

Executive Summary

Prior to its previously announced acquisition by Celgene, private biotech Acetylon Pharmaceuticals Inc. is divesting certain assets outside of Celgene’s areas of focus into a new company, Regenacy Pharmaceuticals LLC, which will have exclusive worldwide rights to these select Acetylon programs and related patents.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Divestiture/Spin-Out

Related Companies